Month: June 2020

Mortsel / Belgium, June 11, 2020 – 8.45 a.m. CETAgfa today announced its intention to close its printing plate factories in Pont-à-Marcq (France) and Leeds (United Kingdom).Faced with a significant and structural decline in demand in the extremely competitive offset printing market, Agfa has to optimize its printing plate manufacturing capacity by adjusting it to the changing market conditions. The decline in demand is characterized by a strong drop in printing plate volumes and substantial price erosion. Both plants produce Agfa’s Thermofuse printing plates. The market demand for this product declines even more substantially than for most other Agfa printing plates. Unfortunately the market forecasts do not suggest any improvement in the years to come.In order to be able to continue its printing plate activities in a sustainable way,...

Mortsel / België, 11 juni 2020 – 8.45 uur CETAgfa kondigde vandaag de intentie aan om zijn drukplaatfabrieken in Pont-à-Marcq (Frankrijk) en Leeds (Verenigd Koninkrijk) te sluiten.Door de aanzienlijke en structurele afname van de vraag in de extreem competitieve offsetdrukmarkt is Agfa genoodzaakt om zijn productiecapaciteit te optimaliseren door haar aan de veranderende marktomstandigheden aan te passen. De achteruitgang van de vraag gaat gepaard met een sterke afname van de drukplatenvolumes en aanzienlijke prijserosie. Beide vestigingen produceren Agfa’s Thermofuse-drukplaten. De marktvraag naar dit product daalt zelfs nog sterker dan voor de meeste andere drukplaten van Agfa. Helaas tonen de marktvooruitzichten geen verbetering in de komende jaren.Om zijn drukplaatactiviteiten op een duurzame manier voort te kunnen zetten, moet Agfa...

June 11, 2020AkzoNobel weathering COVID-19 stormAs the complex situation regarding the global pandemic continues to evolve, AkzoNobel (AKZA; AKZOY) remains focused on ensuring employee health and safety and maintaining business continuity.The various steps taken to continue serving customers and rapidly reduce costs are proving successful, while at the same time keeping the organization intact and able to respond quickly to changes in end market demand.During the first quarter, COVID-19 adversely impacted revenue by around minus 5%. Asia was most affected throughout Q1, with other regions impacted only from the second half of March onwards.In more recent months, end market demand has evolved in line with company planning assumptions. Market headwinds were strongest during April and resulted in revenue almost 30% lower versus last year....

Irish Continental Group plc (“ICG” or the “Group”) Trading update The current level of uncertainty and the introduction of travel restrictions across the EU because of the COVID-19 pandemic has led to a significant reduction in current passenger traffic and forward bookings for what is normally the peak Summer passenger season for ICG’s Irish Ferries services. It is very difficult to estimate the full year financial impact on the Group, as the reduction in passenger revenue will be material. In the period from January 1St to the 6Th of June this year car volumes are down 62% with total passenger volumes down 60%. The severity of this reduction in passenger revenue is dependent on the duration and nature of travel restrictions particularly over the peak Summer season. Retention of the Common Travel Area (CTA) between Britain and Ireland...

VANCOUVER, British Columbia, June 11, 2020 (GLOBE NEWSWIRE) — Zadar Ventures Ltd. (the “Company”) (TSX.V – ZAD) (OTCQB – ZADDF) (Frankfurt – ZAV0.F) announces that it has completed its due diligence on French AR/VR company, XRApplied SAS, and intends to enter into a definitive agreement by the end of June 2020. XRApplied, based in Sarlat-la-Canéda, France, is a leader in the development and deployment of AR/VR/MR technologies and assets like AR/VR games and AR/VR Apps. As previously announced, Zadar continues to work with the team at the UNIQORN incubator-accelerator to complete the transaction.About XRApplied The Company has developed a unique solution that removes the barrier to entry for XR and enables businesses and clients to build an engaging brand experience across multiple platforms at an affordable cost....

Novartis worked with US Food and Drug Administration (FDA) to update Beovu (brolucizumab) prescribing information to guide healthcare professionals in their treatment of wet AMD patients1 The update includes characterization of adverse events, retinal vasculitis and retinal vascular occlusion, as part of the spectrum of intraocular inflammation observed in the HAWK & HARRIER trials and noted in the original prescribing information1 Novartis has convened a fully dedicated team collaborating with top global external experts, leveraging the collective multidisciplinary expertise to examine the root causes, potential risk factors and mitigation of these adverse events2 A Safety Review Committee established by Novartis noted that the overall rate of vision loss in the study population was similar between the Beovu and aflibercept arms...

Sanofi to present growth opportunities and development strategy for Dupixent® (dupilumab) in type 2 inflammatory diseasesAdditional data contribute to the growing body of evidence demonstrating Dupixent’s best in class safety profile combined with strong efficacy benefit for atopic dermatitis and further validate it as a standard of care treatment for asthmaDupixent’s unique mechanism of action simultaneously inhibits IL-4 and IL-13, which play a key role in type 2 inflammation in multiple diseasesRecent evidence further supports additional clinical uses in diseases driven by type 2 inflammation including Eosinophilic Esophagitis and a subset of Chronic Obstructive Pulmonary DiseasePARIS – June 11, 2020 – Sanofi commercial and R&D executives will provide an overview of the growth and development strategy for Dupixent® (dupilumab)...

Sanofi va présenter les opportunités de croissance et la stratégie de développement de Dupixent® (dupilumab) dans les maladies inflammatoires de type 2Des données supplémentaires étoffent le corpus croissant de preuves confirmant que le profil de sécurité de Dupixent combiné à un fort avantage d’efficacité dans le traitement de la dermatite atopique et valident son statut de traitement de référence dans l’asthmeLe mécanisme d’action unique de Dupixent permet d’inhiber simultanément les cytokines IL-4 et IL-13, qui jouent un rôle clé dans l’inflammation de type 2 sous-jacente à plusieurs maladiesDes données récentes confortent les applications cliniques supplémentaires de ce médicament dans la prise en charge des maladies médiées par une inflammation de type 2, comme l’œsophagite à éosinophiles et une sous-catégorie de bronchopneumopathie...